natgillin/translations-raw huggingface dataset:
In operation 1920, the entropy decoder 520 determines a location of the last significant transformation coefficient by decoding the information about the horizontal axis direction location and the vertical axis direction location. The entropy decoder 520 decodes the information about the location of the last significant transformation coefficient by using context-adaptive binary arithmetic decoding (CABAD) or variable length decoding (VLD) as an inverse process to the coding process performed by the entropy coder 450, and determines the location of the last significant transformation coefficient. 
Postupak prema zahtjevu 1, naznačen time da određivanje lokacije zadnjeg značajnog koeficijenta transformacije nadalje sadrži: biranje konteksta koji se koristi za dekodiranje binariziranih informacija o lokaciji smjera vodoravne osi i lokaciji smjera okomite osi zadnjeg značajnog koeficijenta transformacije; te provođenje binarnog aritmetičkog adaptivnog dekodiranja konteksta (CABAD) nad binariziranim informacijama u skladu s odabranim kontekstom.
The composition for use according to any one of the preceding claims, wherein the organic solvent is selected from the group consisting of C1-C10 alcohols, esters of C1-C10 alcohols with C1-C10 carboxylic acids and mixtures thereof, and preferably comprises a C1-C6 alcohol and an ester of C1-C6 alcohol with a C2-C6 carboxylic acid. 
Pripravak za primjenu prema bilo kojem od prethodnih zahtjeva, naznačen time, što je organsko otapalo odabrano iz skupine koja se sastoji od Ci-Ci9 alkohola, estera C;-C19 alkohola s Ci-Cio karboksilnim kiselinama 1 njihovih smjesa, a poželjno se sastoji od C;-C$ alkohola i estera C,-Cg alkohola s C2-Cg karboksilnom kiselinom.
<400> 2 tggctctcct accaccatc 19 An in vitro method for obtaining a corticospinal upper motor neuron from a neural stem cell, wherein said method comprises contacting a neural stem cell under conditions adequate for increasing the signal mediated by the CB1 cannabinoid receptor in said cell and under conditions to promote dorsalization of said cell and wherein conditions adequate for increasing the signal mediated by the CB1 cannabinoid receptor involve an increase in the number of Ctip2+ Satb2- cells with respect to the basal levels of at least 5% and involve: 
In vitro postupak dobivanja kortikospinalnog gornjeg motoričkog neurona iz neuralne matične stanice, naznačen time što se navedeni postupak sastoji u stavljanju u kontakt neuralne matične stanice u uvjetima pogodnim za pojačavanje signala posredovanog kanabinoidnim receptorom CB;, u navedenoj stanici i u uvjetima koji potiču dorzaliziranje navedene stanice, te gdje uvjeti pogodni za pojačavanje signala posredovanog kanabinoidnim receptorom CB, uključuju povećanje broja Ctip2+ Satb2-stanica u odnosu na osnovne razine od najmanje 5% i uključuju:
In one embodiment, the humanized IL-6 gene is under control of endogenous mouse regulatory elements. In one aspect, a method is provided for making a humanized mouse, comprising replacing a mouse gene sequence encoding mouse IL-6 with a human gene encoding human IL-6. 
Postupak za stvaranje humaniziranog miša, naznačen time da sadrži zamjenu sekvence mišjeg gena koji kodira mišji IL-6 sa ljudskim genom koji kodira ljudski IL-6 tako da je ljudski IL-6 gen pod kontrolom regulacijskih elemenata endogenog miša.
Rc and RD are independently selected from the group consisting of hydrogen and alkyl. 
Rc i Rp su neovisno odabrani iz skupine koja se sastoji od vodika 1 alkila,
A pronucleotide of formula (I): 
Pronukleotid predstavljen formulom (III):
is selected from hydrogen or R49; 
se bira između vodika ili R46;
The method of para 28, wherein said parent bacterial strain comprises a strain obtained from culture selected from starter cultures, probiotic cultures, and dietary supplement cultures. 
Postupak prema zahtjevu 15, naznačen time da navedeni matični bakterijski soj je soj dobiven iz kulture koja je odabrana od starter kultura, probiotičkih kultura, te kultura dodataka prehrani.
a first gripping element 110, 210, 310, 410 in the form of a handle, the length of which is preferably greater than 200 mm and the two distal and proximal ends of which are directly or indirectly connected to the base 101, 201, 301, 401 (there is no free end), 
- prvi element za hvatanje (110, 210, 310), čija su oba distalni kraj i proksimalni kraj koji su izravno ili neizravno spojeni na krutu cijev ili crijevo (1000) mlaznice (10) i poželjno s osnovicom (101, 201, 301), ima duljinu veću od 200 mm,
means for obtaining layer-2 information including network information table, NIT from the signal frame, wherein the NIT includes a descriptor having the PLP identifier, an identifier of a transmission system, information for a tuning frequency of the transmission system, an active OFDM symbol duration field and a guard interval field, and means for obtaining the PLP identified by the PLP identifier in the layer-1 information and the data slice identified by the data slice identifier in the layer-1 information, wherein the PLP is mapped to a transport stream using the PLP identifier, the identifier of the transmission system, the information for a tuning frequency of the transmission system, the active OFDM symbol duration field and the guard interval field in the descriptor in the NIT; 
sredstva (1803) za dobivanje NIT uključujući identifikator PLP-a (PLP_id) i identifikator sustava prijenosa (transmission_system_id) iz sloj 2, L2 informacije okvira signala, i dobivanje PLP-a koji odgovara identifikatoru PLP-a i identifikatoru sustava prijenosa uključenog u NIT; i sredstva (1804) za dobivanje prijenosnog toka prema kojem je PLP mapiran, gdje deskriptor dostavnog sustava prijenosa uključujući identifikator PLP-a, identifikator sustava prijenosa i aktivno OFDM polje trajanja simbola u TS petlji NIT mapa prenosi tokove do PLP-ova u podatkovnim komadima sustava prijenosa.
Use of E 62, wherein the monoclonal antibody or monoclonal antibody fragment binds to and inhibits the activity of IL-17RA or IL-17RC. 
Uporaba u skladu sa zahtjevom 62, naznačena time, da se monoklonsko antitijelo ili fragment monoklonskog antitijela veže na i inhibira djelovanje IL-17RA ili IL-17RC.
a heavy chain region corresponding to SEQ ID NO: 85 and a light chain region corresponding to SEQ ID NO: 86, or 
regiju teškog lanca koja odgovara SEQ ID NO: 85 i regiju lakog lanca koja odgovara SEQ ID NO: 86, ili
In one embodiment, ring B is phenyl, pyridinyl, pyrimidinyl, or pyrazinyl; each of which may be optionally substituted. In a further embodiment, ring B is substituted by alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, haloalkyl, hal, OH, NH2, NHR″, CN, N3, or NO2. 
Spoj prema patentnom zahtjevu 5, naznačen time što prsten B je fenil, piridinil, pirimidinil ili pirazinil; od kojih svaki može biti izborno supstituiran, poželjno gdje je prsten B supstituiran sa alkil, aril, heteroaril, cikloalkil, heterocikloalkil, aralkil, haloalkil, hal, OH, NH,, NHR", CN, Nz ili NO».
The present invention relates to a process for the preparation of a composition comprising unsaturated compounds, in particular polyunsaturated compounds, which comprises concentrating and purifying the compounds. 
Ovaj izum se odnosi na postupak za dobivanje pripravka koji sadržava nezasićene spojeve, naročito polinezasićene spojeve, koji uključuje koncentriranje i pročišćavanje spojeva.
In one embodiment, the persisting population of genetically engineered T cells comprises a memory T cell. 
T stanica za upotrebu prema patentnom zahtjevu 7, naznačena time što perzistentna populacija genetski modificiranih T stanica sadrži memorijsku T stanicu.
The method of claim 6, further comprising: outputting the hair cell region image corresponding to the frequency band of a amplitude modulated tone in case that the type of the acoustic signal is the amplitude modulated tone, wherein amplitude variation of the amplitude modulated tone is visualized on the hair cell region image. 
Medij za snimanje u skladu s patentnim zahtjevom 1, naznačen time što medij za snimanje sadrži naredbe koje uzrokuju da računalo provodi postupak daljnjeg provođenja: – davanja na izlaz slike područja s cilijarnim stanicama koje odgovara frekvencijskom pojasu amplitudno moduliranog tona u slučaju da je tip zvučnog signala amplitudno modulirani ton, gdje se amplitudnu varijaciju amplitudno moduliranog tona vizualizira na slici područja s cilijarnim stanicama.
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and component (B1) is azoxystrobin. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, le kao komponentu (B) fluopiram.
HPLC is disclosed as the preferred method of isolation of pravastatin from the fermentation broth. 
HPLC je opisan kao poželjna metoda izolacije pravastatina iz fermentacijskog bujona.
reacting an intermediate of formula (VII) with lithium aluminium hydride in a suitable solvent, with the formation of a compound of formula (I), wherein s is 1, herein referred to as compounds of formula (I-d). wherein the variables are as defined in claim 1. 
ROB pri čemu su varijable kako je definirano u zahtjevul; €) reakciju međuprodukta formule (VII) sa litij aluminij hidridom u pogodnom otapalu, uz stvaranje spoja formule (D), pri čemu s je 1, ovdje se nazivaju spojevi formule (I-d).
After filling lyophilization stoppers were placed and the vials loaded in the lyophiliser at 5° C. Lyophilization process was performed as before for Formulations ET-NF A, ET-NF B and ET-NF F (Table IX). 
Nakon punjenja postavljeni su čepovi za liofilizaciju i ampule postavljene u liofilizator na 5?C. Proces liofilizacije je izveden kaoza prethodni slučaj za oblike ET-NF A, ET-NF B i ET-NF F (Tablica IX).
The polymorph according to clause 8, wherein the polymorph exhibits an X-ray powder diffraction pattern having one or more characteristic peaks expressed in degrees 2-theta at about 3.9 +/- 0.3 degrees, about 17.5 +/- 0.3 degrees, and about 22.0 +/- 0.3 degrees 2-theta. 
Polimorf prema zahtjevu 8, naznačen time da polimorf pokazuje uzorak difrakcije X-zraka na prahu koji ima one ili more karakterističnih vrškova izraženih u stupnjevima 2-theta kod oko 3.9 +/- 0.3 stupnjeva, oko 17.5 +H/- 0.3 stupnjeva, te oko 22.0 +/- 0.3 stupnjeva 2-theta.
The apparatus of claim 1 or 2 wherein the output signal of said at least one sensor (24; 58) is indicative of roundness and thickness of the container sidewall under inspection, the information processor (26; 48; 60) being responsive to both of said signals to detect the absence of rotation at the container. 
Stroj u skladu s patentnim zahtjevom 1 ili 2, gdje izlazni signal iz najmanje jednog navedenog osjetila (24; 58) je indikativan za zakrivljenosti i debljine stijenke spremnika kojeg se pregledava, gdje je uređaj za obradu informacija (26; 48; 60) osjetljiv na oba navedena signala, radi detekcije odsutnosti zakretanja spremnika.
Information on the preparation of necessary starting materials or related compounds (which may be adapted to form necessary starting materials) may also be found in the following Patent and Application Publications, the contents of the relevant process sections of which are hereby incorporated herein by reference: WO 94/27965, WO 95/03283, WO 96/33977, WO 96/33978, WO 96/33979, WO 96/33980, WO 96/33981, WO 97/30034, WO 97/38994, WO 01/66099, U.S. Pat. No. 5,252,586, EP 520 722; EP 566 226, EP 602 851 and EP 635 507. 
Informacija o pripravi potrebnih polaznih materijala ili srodnih spojeva (koji mogu biti prilagođeni tako da tvore polazne materijale) može se također pronaći u slijedećim Patentnim i Prijavnim Publikacijama, iz kojih su sadržaji relevantnih poglavlja o postupcima povezani sa ovim dokumentom: WO 94/27965, WO 95/03283, WO 96/33977, WO 96/33978, WO 96/33979, WO 96/33980, WO 96/33981, WO 97/30034, WO 97/38994, WO 01/66099, US 5,252,586, EP 520 722, EP 566 226, EP 602 851 i EP 635 507.
A method of treating a PI3K-related disorder or an mTOR-related disorder, comprising administering to a mammal in need thereof a compound of any one of claims 1-13 in an amount effective to treat a PI3K-related disorder. The method of claim 18, wherein the PI3K-related disorder or the mTOR-related disorder is selected from restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, atherosclerosis, inflammation, angiogenesis, immunological disorders, pancreatitis, kidney disease, and cancer. 
Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što je namijenjen upotrebi u liječenju poremećaja povezanog s PI3K ili poremećaja povezanog s mTOR, gdje se poremećaj povezan s PI3K ili poremećaj povezan s mTOR bira između restenoze, ateroskleroze, poremećaja kostiju, artritisa, dijabetične retinopatije, psorijaze, dobroćudne hipertrofije prostate, ateroskleroze, upale, angiogeneze, imunoloških poremećaja, pankreatitisa, bolesti bubrega, te raka.
The composition according to claim 13, wherein the plasticizer is triethyl citrate and glycerol monostearate. 
Pripravak u skladu sa zahtjevom 10, naznačen time, da plastifikator je trietil citrat i glicerol monostearat.
A compound of formula (I), a N -xide form, an addition salt or a stereochemically isomeric form thereof, wherein m is 0, 1, or 2 and when m is 0 then a direct bond is intended; 
Spoj formule (I), [image] njegov N-oksidni oblik, adicijska sol ili stereokemijski izomerni oblik, naznačen time, da m je 0, 1, ili 2 i kada m je 0 tada je namjeravana direktna veza;
Use of a magnesia cement defined in any one of claims 1 to 12 for the manufacture of monolithic lining, precast shapes, prefabricated elements, functional products, fireproof products and/or insulating products for furnaces, vessels or other devices used in the refractory, steel, non-ferrous metals, cement, glass, ceramic, electronic, construction, and other industries. 
Uporaba magnezijskog cementa definiranog u bilo kojem od zahtjeva 1 do 12, za proizvodnju monolitne obloge, montažnih oblika, montažnih elemenata, funkcionalnih proizvoda, proizvoda otpornih na vatru iili izolirajućih proizvoda za peći, posuda ili drugih uređaja koji se koriste u refraktornim, čeličnim, ne-željeznim metal, cementnim, staklenim, keramičkim, elektroničkim, konstrukcijskim 1 ostalim industrijama.
the second light chain and the second heavy chain of a second antibody which specifically binds to CD3, and wherein the variable domains VL and VH in the second light chain and second heavy chain of the second antibody are replaced by each other; and wherein 
drugi laki lanac i drugi teški lanac drugog antitijela koje se specifično veže za CD3, i gdje su varijabilne domene VL i VH u drugom lakom lancu i drugom teškom lancu drugog antitijela zamijenjene jedna drugom i
-[(2S)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, or a therapeutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 18, naznačen time, da je spoj 2-[(2S)-2-metilpirolidin-2-il]-1H-benzimidazol-4-karboksamid ili terapijski prihvatljiva njegova sol.
wherein both said first and second cam elements (31, 41) are unitary with said pin (20) in such a manner to unitary rotate therewith, and wherein said pin (20) is interposed between said first and second plunger elements (32, 42). 
Spojnica za zatvaranje vrata prema zahtjevu 1, gdje su prvi i drugi klipni elementi (32, 42) uzajamno nasuprotni u odnosu na klin (20). Spojnica za zatvaranje vrata prema zahtjevu 1 ili 2, gdje su barem jedna prva i druga ravnina (1', m", 1 paralelne.
In one embodiment, the acidic variants are evaluated by a method selected from the group consisting of ion exchange chromatography wherein the composition is treated with sialidase, reduced capilliary electrophoresis with sodium dodecyl sulfate (CE-SDS), non-reduced CE-SDS, boronate chromatography, and peptide mapping. BRIEF DESCRIPTION OF THE DRAWINGS FIG. 
Postupak prema zahtjevu 13 ili 14, naznačen time, da korak (2) obuhvaća procjenjivanje kiselinskih varijanti putem postupka koji je odabran iz skupine koju čine kromatografija ionske izmjene gdje se sastav obrađuje sa sialidazom, reducirana kapilarna elektroforezija s natrijevim dodecilsulfatom (CE-SDS), nereducirana CE-SDS, boronatna kromatografija i peptidno mapiranje.
A compound or salt or solvate thereof represented by Formula (I): [wherein, 
PATENTNI ZAHTJEVI Spoj, njegova ili sol ili solvat, prikazan Formulom (1):
A composition comprising an orodispersible dose of desmopressin of 25 µg measured as the free base of desmopressin, for use in reducing nocturnal voids in a female patient in need thereof, wherein the dose is for administration to the patient prior to bedtime and reduces the patient's nocturnal voids compared to before administration, and wherein the mean reduction in nocturnal voids at week 52 of administration is increased compared to the mean reduction in nocturnal voids at day 28 of administration. 
PATENTNI ZAHTJEVI M» Pripravak koji sadrži orodisperzibilnu dozu od 25 ug ili 50 ug desmopresina mjerenu kao slobodnu bazu desmopresina, za upotrebu u smanjenju nokturije kod muškog pacijenta kojem je to potrebno, pri čemu je doza za davanje pacijentu prije spavanja i smanjuje noćna buđenja kod pacijenta u usporedbi s prije primjene, te pri čemu se srednje smanjenje noćnih buđenja u 52. tjednu primjene povećava u usporedbi sa srednjim smanjenjem noćnih buđenja 28. dana primjene.
Dermatological composition comprising heparan sulphate and one or more of the following ingredients: preservatives, emulsifiers, stabilizers, humectants, anti-oxidants, wherein heparan sulfate is present at a concentration comprised between 0.5 % by weight and 5 % by weight. 
PATENTNI ZAHTJEVI 1. - Dermatološki pripravak koji sadrži heparan sulfat 1 jedan ili više od slijedećih sastojaka: konzervansi, emulgatori, stabilizatori, humektanti, antioksidanti, pri čemu je heparan sulfat prisutan u koncentraciji između 0,5 % 15 % ukupne mase.
Compounds of formula I that contain a nitrogen can be reacted with an alkylating agent such as chloromethylacetate and the like to give a prodrug that, upon biotransformation, can release compounds of formula I. 
Spojevi formule I koji sadrže dušikov atom mogu reagirati sa sredstvom za alkiliranje kao što je klororaetilacetat i slično pri čemu se dobiva prolijek koji nakon transformacije može prijeći u spojeve formule I.
A particularly preferred isomer is isomer (la), i.e. the 2 S,3 S,11b R isomer of 3,11b- cis -dihydrotetrabenazine. 
Posebno povoljan izomer je izomer (Ta), to je 25,35,11bR izomer 3,11b-cis-dihidrotetrabenazina.
% w/w of hydroxypropyl methylcellulose; and % w/w of glyceryl behenate. The compound for use according to claim 1 or claim 2, wherein the compound is administered to the subject as one or more capsules which comprise: 
Spoj za uporabu prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time što se spoj daje subjektu kao jedna ili više kapsula koje sadrže: 100 mg hemitartratne soli navedene strukturne formule; 45.0 mg mikrokristalne celuloze; 111.5 mg laktoze monohidrata; 10.8 mg hidroksipropil metilceluloze; i 2.7 mg gliceril behenata.
The computer program product of claim 2, wherein the using one or more parameters comprises adding a value of a base address register of the function table entry to the offset to obtain the data address. 
Postupak prema zahtjevu 2, gdje uporaba jednog ili više parametara obuhvaća dodavanje vrijednosti iz baze registra adresa iz unosa funkcijske tablice pomaku radi dobivanja podatkovne adrese.
In the ULV™ model, available from Pioneer Hi-Bred International, instead of a large water tank, either as a pre-mix tank or water supply tank, again a much smaller single container (e.g. 
Kod ULVTM modela, koji se može nabaviti od Pioneer Hi-Bred International, umjesto velikog spremnika vode, bilo kao spremnika prethodno načinjene mješavine, bilo kao spremnika za opskrbu vodom, opet jedna jedina mala posuda (npr.
The following working Example serves to better illustrate, but not limit, embodiments of the present invention. 
Slijedeći radni primjer služi da bi bolje ilustrirao, ali bez ograničenja, varijante ovo izuma.
Selection of excipients and the amounts used may be readily determined by the formalation scientist based upon experience and consideration of standard procedures and reference works in the field. 
Izbor pomoćnih tvari i korištenih količina može lako odrediti stručnjak za oblikovanje na temelju iskustva i uzimajući u obzir standardne postupke i referentne radove iz struke.
For in vivo embodiments, the contacting step is effected in a subject and includes administering an anti-GCC antibody molecule or immunoconjugate thereof to the subject under conditions effective to permit both binding of the antibody molecule to the extracellular domain of GCC expressed on the cell, and the treating of the cell. 
Postupak za proizvodnju molekula antitijela prema bilo kojem od patentnih zahtjeva 1 do 3, koji obuhvaća uzgajanje stanice koja sadrži izolirane sekvence nukleinske kiseline prema patentnom zahtjevu 5 ili vektor prema patentnom zahtjevu 6, pod uvjetima koji omogućavaju proizvodnju molekula antitijela, čime se proizvodi molekula antitijela.
wherein the compound of formula (I) is present in a pharmaceutical composition. The pharmaceutical composition of claim 1, wherein the compound has an effect on mutant CFTR protein, wherein the mutant CFTR is a mutation AF508-CFTR, or another mutation of class II, and wherein a mutation AF508-CFTR, or another mutation of class II are involved in CFTR protein malfunction. 
Tvar za uporabu u skladu s patentnim zahtjevom 1 ili 2 ili 3, pri čemu ona ima učinak na mutirani CFTR protein, pri čemu je navedena mutacija CFTR mutacija ∆F508-CFTR, ili druga mutacija klase II i pri čemu su mutacija ∆F508-CFTR, ili druga mutacija klase II uključene u nepravilnost funkcije CFTR proteina.
Potassium Sorbate Preservative 
3,0 kalijev sorbat konzervans
Field of the Invention The present invention relates generally to glassware forming machines, and more particularly to an invert arm assembly for an individual section glassware forming machine. 
Područje primjene Izuma Ovaj izum općenito se odnosi na strojeve za obradu stakla, podrobnije na sklop invertirajuće ruke za pojedinačni dio stroja za oblikovanje stakla.
A developer supply container according to any one of Claims 1 - 25, wherein said developer accommodating chamber (2k) is substantially non-rotatable, and wherein said feeding portion (2c) includes a shaft portion rotatable relative to said developer accommodating chamber (2k) by the rotational force and a feeding blade portion fixed to said shaft portion configured and positioned to feed the developer toward said discharge opening (3a). 
Spremnik za nadopunjavanje razvijača u skladu s bilo kojim od patentnih zahtjeva 1-25, naznačen time što navedena komora za držanje razvijača (2k) uglavnom nije zakretljiva, te gdje navedeni dio za punjenje (2c) uključuje vratilo zakretljivo u odnosu na navedenu komoru za držanje razvijača (2k) zbog sile vrtnje i punjač s lopaticama pričvršćen na navedeno vratilo tako konfiguriran i na takvom mjestu da šalje razvijač prema navedenom otvoru za ispuštanje (34).
Figure 1 depicts XRPD patterns for the monoclinc form (upper pattern) and the orthorhombic form (lower pattern) of asenapine maleate. 
Slika Ipredstavlja XRPD uzorke monoklinskog oblika (gornji uzorak) i ortorombskog oblika (donji uzorak) asenapin maleata.